Eye Drop

WAILEA, Hawaii — In this Healio video perspective, Mark L. Baum, chairman and CEO at Harrow, discusses the launch of Vevye ophthalmic solution for the treatment of dry eye disease, here at Hawaiian Eye 2024.

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.

At OSN New York 2023, Eric D. Donnenfeld, MD, and a panel of corneal experts assembled to discuss hot topics such as NSAID use after cataract surgery and dropless regimens.

Harrow announced three partnerships to support the upcoming launch of Vevye, indicated for treating the signs and symptoms of dry eye disease.

Nicox announced that the first patient has been screened in its Whistler phase 3b clinical trial of NCX 470, a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension.

SAN FRANCISCO — Ophthalmologists can reduce unnecessary waste by changing the way they use topical drops, according to a speaker at the American Academy of Ophthalmology meeting.

Oculis has announced the first patient first visit in its phase 2b RELIEF trial evaluating licaminlimab, the company’s novel anti-tumor necrosis factor-alpha biologic eye drop, for treatment of moderate to severe dry eye disease.

Oh my. Another FDA recall of generic artificial tears hit the news during eyeball month.

Bausch + Lomb has collected 464,100 pounds of used contact lenses, eye care and lens care materials through its One by One and Biotrue Eye Care recycling programs, according to a company press release.

Kilitch Healthcare India Limited has voluntarily recalled 25 over-the-counter eye drop products after the FDA warned of unsanitary conditions and potential safety concerns, according to a company press release.